GlassScriptPhysician profile
George Pancio
NPI 1427053743
$1,517.70
in general payments reported to CMS, 2019-2025
23 companies · $204 in 2025
The $204 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.19 · 2021: $61.95 · 2022: $426 · 2023: $518 · 2024: $294 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,015.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $468.18 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.55 | 2023-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $117.56 | 2021-2024 | Xarelto |
| Amgen INC. | $114.18 | 2022-2023 | Repatha |
| Pfizer INC. | $110.02 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $78.59 | 2022-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $52.16 | 2022-2023 | |
| Alnylam Pharmaceuticals INC. | $40.56 | 2022-2024 | Onpattro |
| Irhythm Technologies, INC. | $36.68 | 2023 | Zio Xt Patch |
| E.R. Squibb & Sons, L.L.C. | $35.95 | 2022-2023 | Eliquis |
| Inspire Medical Systems, INC. | $35.14 | 2024-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $35.10 | 2020-2024 | Farxiga |
| Becton, Dickinson and Company | $32.54 | 2025 | |
| Bardy Diagnostics, INC. | $29.00 | 2022 | |
| Novo Nordisk INC | $28.65 | 2025 | Wegovy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $28.48 | 2024 | Optimizer |
| Kestra Medical Technology Services, INC. | $27.84 | 2023 | Assure Wcd |
| Abbott Laboratories | $25.77 | 2021 | |
| Edwards Lifesciences Corporation | $23.36 | 2023 | Sapien 3 Ultra Resilia |
| Cvrx, INC. | $22.16 | 2023 | Barostim Neo System |
| Boston Scientific Corporation | $20.55 | 2025 | Watchman Flx |
| Scpharmaceuticals INC. | $15.67 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $15.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Pancio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.